Hypera SA (HYPMY)
OTHER OTC:HYPMY
Top Page
Hypera SA
(OTC:HYPMY)
Select Model
Select Model
Rating:74Outperform
Price Target:
$5.00
▲(16.01% Upside)
Action:UpgradedDate:04/11/26
The score is driven primarily by solid financial performance with healthy margins and renewed revenue growth, tempered by weaker cash conversion and reduced profitability versus prior years. Technicals are supportive with an established uptrend, while valuation is a clear positive due to the low P/E and strong dividend yield.
Positive Factors
High margins and pricing power
Sustained gross (~58%) and net (~16%) margins indicate durable pricing power from branded OTC and generics. High margins support reinvestment, cover SG&A and capex, and provide a long-term earnings cushion versus commodity or low-margin peers.
Negative Factors
Weak cash conversion
Subpar cash conversion—OCF covering <50% of EBIT and FCF ~67% of net income—signals working-capital drag or higher cash taxes/interest/capex. This limits self-funding, reduces flexibility for M&A or buybacks, and raises vulnerability to earnings volatility.
Read all positive and negative factors
Positive Factors
Negative Factors
High margins and pricing power
Sustained gross (~58%) and net (~16%) margins indicate durable pricing power from branded OTC and generics. High margins support reinvestment, cover SG&A and capex, and provide a long-term earnings cushion versus commodity or low-margin peers.
Read all positive factors
Hypera SA (HYPMY) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.34B
Dividend Yield4.73%
Average Volume (3M)110.00
Price to Earnings (P/E)12.0
Beta (1Y)0.72
Revenue Growth-18.21%
EPS Growth-50.94%
CountryUS
Employees10,481
SectorHealthcare
Sector Strength45
IndustryDrug Manufacturers - Specialty & Generic
Share Statistics
EPS (TTM)0.13
Shares Outstanding633,420,840
10 Day Avg. Volume0
30 Day Avg. Volume110
Financial Highlights & Ratios
PEG Ratio-1.11
Price to Book (P/B)1.15
Price to Sales (P/S)1.86
P/FCF Ratio8.08
Enterprise Value/Market Cap7.27
Enterprise Value/Revenue3.16
Enterprise Value/Gross Profit5.35
Enterprise Value/Ebitda10.75
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Hypera SA Business Overview & Revenue Model
Company Description
Hypera S.A. operates as a pharmaceutical company in Brazil. It offers prescription products under the Adacne, Addera, apri, AmpliumG, please, Celestamine, Celestone, Celestone Soluspan, Cizax, deciprax, Derive C Micro, Micro Drift, Dermotil Fusid,...
How the Company Makes Money
Hypera makes money mainly by selling pharmaceutical and consumer health products in Brazil. Its core revenue stream is net sales of finished products (i.e., branded OTC medicines and prescription products, including branded generics) sold through ...
Hypera SA Earnings Call Summary
Earnings Call Date:Oct 28, 2025
(Q3-2025)
| % Change Since: |
Next Earnings Date:Apr 28, 2026
Earnings Call Sentiment Positive
The earnings call highlighted significant achievements, including strong revenue growth, successful working capital optimization, and record operational cash flow. However, challenges were noted in the institutional market and R&D approval delays. Despite these challenges, the overall performance and strategic initiatives indicate a positive outlook.Positive Updates
Successful Working Capital Optimization
The company successfully concluded its working capital optimization process, leading to improved operational cash generation without impacting sell-out or profitability.
Negative Updates
Decline in Institutional Market Sales
Net revenue from the institutional market decreased by 4% due to a lower level of sales to the public market.
Read all updates
Q3-2025 Updates
Positive
Negative
Successful Working Capital Optimization
The company successfully concluded its working capital optimization process, leading to improved operational cash generation without impacting sell-out or profitability.
Read all positive updates
Company Guidance
In the third quarter of 2025, Hypera Pharma demonstrated strong financial and operational performance, driven by strategic initiatives and market dynamics. The company successfully completed its working capital optimization process, which led to a significant improvement in operational cash generation without affecting sell-out or profitability. Sell-out increased by nearly 2 percentage points above the market and 3 percentage points above the growth in the second quarter, with particular strength in influenza medication, pain killers, and skincare products. Hypera maintained its operational profitability with an EBITDA of approximately BRL 760 million and a 34% margin, which was an improvement over previous quarters. Net revenue grew by 16% to BRL 2.2 billion, despite a 4% reduction in the institutional market, attributed to lower public market sales. The company's gross margins stood at 61.2%, and they reported a reduced investment in working capital, which now represents 30% of net revenue, down from previous years. Hypera also approved BRL 185 million in shareholder payments and strengthened its corporate governance. Looking ahead, the company plans to leverage its strong brand portfolio and innovation pipeline, with significant opportunities expected from the expiration of the semaglutide patent and other molecules.Hypera SA Financial Statement Overview
Summary
Income Statement
76
Positive
Balance Sheet
68
Positive
Cash Flow
61
Positive
| Breakdown | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 7.70B | 7.44B | 7.91B | 7.55B | 5.94B |
| Gross Profit | 4.55B | 4.38B | 5.00B | 4.76B | 3.80B |
| EBITDA | 2.26B | 2.23B | 2.88B | 2.77B | 2.16B |
| Net Income | 1.20B | 1.34B | 1.65B | 1.70B | 1.33B |
Balance Sheet | |||||
| Total Assets | 25.16B | 24.56B | 24.51B | 23.76B | 19.82B |
| Cash, Cash Equivalents and Short-Term Investments | 1.65B | 1.74B | 2.58B | 2.86B | 2.29B |
| Total Debt | 9.34B | 9.40B | 9.96B | 9.68B | 7.41B |
| Total Liabilities | 12.63B | 12.46B | 12.99B | 13.10B | 9.98B |
| Stockholders Equity | 12.52B | 12.10B | 11.50B | 10.65B | 9.83B |
Cash Flow | |||||
| Free Cash Flow | 1.78B | 1.77B | 1.58B | 529.34M | 560.25M |
| Operating Cash Flow | 2.57B | 2.54B | 2.40B | 2.04B | 1.40B |
| Investing Cash Flow | -689.50M | -592.44M | -791.19M | -1.74B | -4.41B |
| Financing Cash Flow | -1.98B | -2.79B | -1.89B | 278.95M | 557.06M |
Hypera SA Technical Analysis
Positive
4.31
Price Trends
4.36
Positive
4.40
Positive
4.37
Positive
Market Momentum
0.09
Negative
63.43
Neutral
100.18
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HYPMY, the sentiment is Positive. The current price of 4.31 is below the 20-day moving average (MA) of 4.36, below the 50-day MA of 4.36, and below the 200-day MA of 4.37, indicating a bullish trend. The MACD of 0.09 indicates Negative momentum. The RSI at 63.43 is Neutral, neither overbought nor oversold. The STOCH value of 100.18 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for HYPMY.
Hypera SA Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $3.34B | 12.00 | 9.86% | 4.73% | -18.21% | -50.94% | |
67 Neutral | $1.76B | 14.40 | 15.55% | ― | 48.87% | ― | |
58 Neutral | $3.82B | 21.36 | -98.94% | ― | -0.25% | ― | |
55 Neutral | $2.92B | -72.78 | -3.67% | ― | 4.54% | -130.59% | |
54 Neutral | $3.95B | 54.80 | -67.91% | ― | 9.50% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
48 Neutral | $1.49B | -1.35 | -35.16% | 8.48% | -2.55% | 66.00% |
* Healthcare Sector Average
HYPMY
Hypera SA
4.68
1.52
48.13%
PRGO
Perrigo Company
10.86
-12.18
-52.87%
SUPN
Supernus Pharmaceuticals
50.68
19.01
60.03%
ANIP
ANI Pharmaceuticals
78.36
10.24
15.03%
INDV
Indivior
30.54
21.43
235.24%
AMRX
Amneal Pharmaceuticals
12.54
5.56
79.66%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.